The Yale ADRC seeks to advance our understanding of Alzheimer's disease with the eventual goal of translating laboratory discoveries into novel effective clinical therapies. Five Cores (Administrative, Clinical, Data, Biomarker/Pathology and Outreach) and 3 Research Projects (Lysosomes, Post-Synaptic Densities and GABAergic Networks) will work together to achieve this goal. Our unifying theme is a focus on the cell biology of specific neurons, and its disruption in Alzheimer's disease triggered by abnormal forms of Amyloid-? peptide. Research Projects will focus on specific neuronal organelles and specific neuronal subtypes perturbed in disease and make use of human tissue analysis and human subject imaging to evaluate mechanistic hypotheses. The Biomarker/Pathology Core will develop novel, sensitive and high-throughput mass spectrometry assays by targeted multiple-reaction monitoring (MRM) to monitor disease mechanisms. A key emphasis will be the translational development of research findings into therapeutic benefit. To support the future strength of Alzheimer's research, the Yale ADRC will strive to advance the careers of Young Investigators through mentorship from a distinguished Internal Advisory Committee, and through Pilot Project awards. In addition to collecting clinical data and biospecimens of brain, CSF, DNA, serum, blood cells and iPSCs for analysis by members of the ADRC research team, the ADRC will support other Yale NIH-funded research studies on related topics and contribute materials to national NIA-sponsored research networks. The Outreach Core will connect with the community to provide greater knowledge regarding Alzheimer's disease and related dementia.
The Yale Alzheimer Disease Research Center (ADRC) seeks to advance our understanding of Alzheimer's disease with the eventual goal of translating laboratory discoveries into novel effective clinical therapies. Five Cores (Administrative, Clinica, Data, Biomarker/Pathology and Outreach) and 3 Research Projects (Lysosomes, Post-Synaptic Densities and GABAergic Networks) will work together to achieve this goal. Our unifying theme is a focus on the cell biology of specific neurons, and its disruption in Alzheimer's disease triggered by abnormal forms of Amyloid-? peptide.
|Kent, Brianne A; Strittmatter, Stephen M; Nygaard, Haakon B (2018) Sleep and EEG Power Spectral Analysis in Three Transgenic Mouse Models of Alzheimer's Disease: APP/PS1, 3xTgAD, and Tg2576. J Alzheimers Dis 64:1325-1336|
|van Dyck, Christopher H (2018) Anti-Amyloid-? Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. Biol Psychiatry 83:311-319|
|Nygaard, Haakon B; Erson-Omay, E Zeynep; Wu, Xiujuan et al. (2018) Whole Exome Sequencing of an Exceptional Longevity Cohort. J Gerontol A Biol Sci Med Sci :|
|Kaur, Antarpreet; Edland, Steven D; Peavy, Guerry M (2018) The MoCA-Memory Index Score: An Efficient Alternative to Paragraph Recall for the Detection of Amnestic Mild Cognitive Impairment. Alzheimer Dis Assoc Disord 32:120-124|
|Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679|
|Condello, Carlo; Yuan, Peng; Grutzendler, Jaime (2018) Microglia-Mediated Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging. Biol Psychiatry 83:377-387|
|Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416|
|Brenowitz, Willa D; Han, Fang; Kukull, Walter A et al. (2018) Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. Neurobiol Aging 62:64-71|
|Ferguson, Shawn M (2018) Neuronal lysosomes. Neurosci Lett :|
|Gallagher, Damien; Kiss, Alex; Lanctot, Krista L et al. (2018) Toward Prevention of Mild Cognitive Impairment in Older Adults With Depression: An Observational Study of Potentially Modifiable Risk Factors. J Clin Psychiatry 80:|
Showing the most recent 10 out of 134 publications